Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

ABSTRACT:

Importance

Obsessive-compulsive disorder (OCD) is one of the world's most disabling illnesses according to the World Health Organization. Serotonin reuptake inhibitors (SRIs) are the only medications approved by the Food and Drug Administration to treat OCD, but few patients achieve minimal symptoms from an SRI alone. In such cases, practice guidelines recommend adding antipsychotics or cognitive-behavioral therapy consisting of exposure and ritual prevention (EX/RP).

Objective

To compare the effects of these 2 SRI augmentation strategies vs pill placebo for the first time, to our knowledge, in adults with OCD.

Design, setting, and participants

A randomized clinical trial (conducted January 2007-August 2012) at 2 academic outpatient research clinics that specialize in

SUBMITTER: Simpson HB 

PROVIDER: S-EPMC3955365 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature